Chromosome, great point (as well as NS's comment on a PR).
It leaves everyone wondering (1) what did we lose in the first place (there was never confirmation that it was actually CVS that was dropped, IIRC)?, (2) which formularies does this pertain to? (ie. ALL CVS formularies?, Group? Individual? only SPECIFIC groups?, etc.) (3) how was pricing impacted?
.
Amarin/Sarissa make analyzing our investment so damn difficult sometimes. I realize they can't share everything for competitive reasons (ie. pricing), but geez. Give us something.
Market Data 
Markets 
AI
